GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment

Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Senores Pharmaceuticals Ltd
Senores Pharmaceuticals: Board Approves Re-appointments of MD and WTD
BOARD ▲ Positive Development LOW RISK
📅 Filed on BSE: 13 Oct 2026, 12:18 PM IST  ·  BSE ID: 13f9f5e7-6bdd-4c1f-ba5e-1c1ff88e22dc
View Original BSE Filing (PDF)
💡
In Simple Terms
The company's board re-appointed its Managing Director and Whole Time Director for another three years, pending shareholder vote.
🤖 AI Summary
  • Board approved re-appointment of Mr. Swapnil Jatinbhai Shah as MD.
  • Mr. Shah's re-appointment is for three years commencing October 15, 2026.
  • Board approved re-appointment of Mr. Chetan Bipinchandra Shah as WTD.
  • Mr. Shah's re-appointment is for three years commencing November 10, 2026.
  • Both appointments require shareholder approval through postal ballot.
🏢 How This Affects the Company
📈
Business Impact
The re-appointments ensure leadership continuity for Senores Pharmaceuticals, supporting ongoing business strategy execution.
💰
Financial Impact
No direct financial impact is stated in this filing; financial terms of re-appointments are not disclosed.
⚙️
Operational Impact
Stability in key management positions facilitates consistent operational direction and decision-making.
⚠️
Risk Impact
Re-appointment of existing leadership, subject to shareholder approval, maintains established governance pathways.
👥 What This Means For Shareholders
✅
Action Required
Shareholders will need to vote on the re-appointments via postal ballot when issued.
👤
Who Is Affected
All shareholders of Senores Pharmaceuticals will have the opportunity to vote on the proposed re-appointments.
🔍
Management Signal
The Board's decision to re-appoint existing key management indicates confidence in their performance and strategy.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Shareholder voting outcome for MD re-appointment
Shareholder voting outcome for WTD re-appointment
Next quarterly financial results release
LOW RISK Routine management re-appointment pending shareholder approval; no new material risks indicated.
💡 Investor Takeaway
Senores Pharmaceuticals' Board has approved the re-appointment of its Managing Director and Whole Time Director for three-year terms, subject to shareholder consent.
⚖️ Strengths & Concerns

✅ Positives

  • Board continuity: Re-appointment of experienced Managing Director for a three-year term ensures stable leadership.
  • Board continuity: Re-appointment of Whole Time Director for a three-year term ensures continued operational oversight.
❓ Frequently Asked Questions
Who has been re-appointed as Managing Director of Senores Pharmaceuticals?
Mr. Swapnil Jatinbhai Shah has been re-appointed as the Managing Director of Senores Pharmaceuticals.
For how long has Mr. Swapnil Jatinbhai Shah been re-appointed as MD?
Mr. Swapnil Jatinbhai Shah has been re-appointed for a period of three (3) consecutive years.
When does the re-appointment of Mr. Swapnil Jatinbhai Shah as MD take effect?
The re-appointment of Mr. Swapnil Jatinbhai Shah as MD takes effect from October 15, 2026, subject to shareholder approval.
Who has been re-appointed as Whole Time Director of Senores Pharmaceuticals?
Mr. Chetan Bipinchandra Shah has been re-appointed as the Whole Time Director of Senores Pharmaceuticals.
When does the re-appointment of Mr. Chetan Bipinchandra Shah as WTD take effect?
The re-appointment of Mr. Chetan Bipinchandra Shah as WTD takes effect from November 10, 2026, subject to shareholder approval.

Questions based on this BSE filing only. For information purposes.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.